A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy and tolerability of AFQ056 in reducing L-dopa induced dyskinesias in Parkinson’s patients with severe motor complications

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

•To assess the potential anti-dyskinetic efficacy of multiple titrated doses of AFQ056 in Parkinson’s patients with severe L-dopa induced dyskinesias using the Abnormal Involuntary Movement Scale (AIMS). •To assess the potential anti-parkinsonian effect of multiple titrated doses of AFQ056 in combination with L-dopa in Parkinson’s patients with severe L-dopa induced dyskinesias using the Unified Parkinson’s Disease Rating Scale (UPDRS) – part III. •To assess the safety and tolerability of multiple titrated doses of AFQ056 in combination with L-dopa in Parkinson’s patients with severe L-dopa induced dyskinesias .

Critère d'inclusion

L-dopa induced dyskinesias in Parkinson’s patients with severe motor complications

Liens

ictrp
euctr

Kusajili – Centralise les essais cliniques mondiaux

A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy and tolerability of AFQ056 in reducing L-dopa induced dyskinesias in Parki...